Review our commercial product billing guide
Dec. 2023Important Notices
Pennsylvania Act 1 of 2023, signed into law this May, requires insurance policies to cover all costs associated with one supplemental breast screening every year for women with increased risk of breast cancer via MRI or ultrasound.
To assist providers in navigating this new law, we are offering recommendations as a guide to aid with compliance.
We encourage you to review our commercial product billing guide for recommendations around complying with Pennsylvania Act 1 of 2023.
If you have any questions or concerns, please contact your physician account executive or call Provider Services at 1-866-918-1595.
To assist providers in navigating this new law, we are offering recommendations as a guide to aid with compliance.
We encourage you to review our commercial product billing guide for recommendations around complying with Pennsylvania Act 1 of 2023.
If you have any questions or concerns, please contact your physician account executive or call Provider Services at 1-866-918-1595.
Recent Announcements
Voluntary nationwide recall: Famotidine (Fresenius – November)
Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.Nov. 2025Pharmacy Updates
Medicaid provider update: High-cost Medicaid drug billing
Billing requirements for Medicaid-covered drugsNov. 2025Important Notices
Training Webinar: Conversio Health COPD Management Program
Please join us for a live training webinar for primary care providers and pulmonologists by UPMC Health Plan that will provide an overview of a comprehensive COPD management program from Conversio Health.Nov. 2025Education/Webinars